JP2024519545A5 - - Google Patents
Info
- Publication number
- JP2024519545A5 JP2024519545A5 JP2023573168A JP2023573168A JP2024519545A5 JP 2024519545 A5 JP2024519545 A5 JP 2024519545A5 JP 2023573168 A JP2023573168 A JP 2023573168A JP 2023573168 A JP2023573168 A JP 2023573168A JP 2024519545 A5 JP2024519545 A5 JP 2024519545A5
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- specific antibody
- composition according
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194470P | 2021-05-28 | 2021-05-28 | |
| US63/194,470 | 2021-05-28 | ||
| US202163209694P | 2021-06-11 | 2021-06-11 | |
| US63/209,694 | 2021-06-11 | ||
| PCT/EP2022/064362 WO2022248642A1 (en) | 2021-05-28 | 2022-05-26 | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519545A JP2024519545A (ja) | 2024-05-15 |
| JP2024519545A5 true JP2024519545A5 (cg-RX-API-DMAC7.html) | 2025-05-26 |
Family
ID=82115891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573168A Pending JP2024519545A (ja) | 2021-05-28 | 2022-05-26 | B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220411525A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347039A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240014482A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119679935A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022281104A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024822A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221399A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014139A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022248642A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| EP4426437A4 (en) | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
-
2022
- 2022-05-26 KR KR1020237044376A patent/KR20240014482A/ko active Pending
- 2022-05-26 US US17/825,123 patent/US20220411525A1/en not_active Abandoned
- 2022-05-26 BR BR112023024822A patent/BR112023024822A2/pt not_active Application Discontinuation
- 2022-05-26 CA CA3221399A patent/CA3221399A1/en active Pending
- 2022-05-26 WO PCT/EP2022/064362 patent/WO2022248642A1/en not_active Ceased
- 2022-05-26 EP EP22731534.8A patent/EP4347039A1/en active Pending
- 2022-05-26 AU AU2022281104A patent/AU2022281104A1/en not_active Abandoned
- 2022-05-26 MX MX2023014139A patent/MX2023014139A/es unknown
- 2022-05-26 JP JP2023573168A patent/JP2024519545A/ja active Pending
- 2022-05-26 CN CN202411436609.3A patent/CN119679935A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peters et al. | Pathophysiology and treatment of psoriasis | |
| JP2022180461A5 (cg-RX-API-DMAC7.html) | ||
| JP2024523003A5 (cg-RX-API-DMAC7.html) | ||
| JP2004512262A5 (cg-RX-API-DMAC7.html) | ||
| AR040603A1 (es) | El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos | |
| Katsambas et al. | A double‐blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream | |
| JP2023517243A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526595A5 (cg-RX-API-DMAC7.html) | ||
| JP2022188083A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537927A5 (cg-RX-API-DMAC7.html) | ||
| DE112011102638T5 (de) | Pharmazeutische Zusammensetzung und Verfahren zur Behandlung und Prävention der Krankheiten, die durch HIV verursacht werden oder mit HIV zusammenhängen | |
| JP2022116304A (ja) | 血液がんの治療のためのPPARγアゴニスト | |
| JP2020512361A5 (cg-RX-API-DMAC7.html) | ||
| JP2020523384A5 (cg-RX-API-DMAC7.html) | ||
| JP2022523530A5 (cg-RX-API-DMAC7.html) | ||
| JP2022028788A5 (cg-RX-API-DMAC7.html) | ||
| JP2021075563A (ja) | 15−オキソ−epaまたは15−オキソ−dglaを含む組成物、ならびにその作製及び使用方法 | |
| RU2007134368A (ru) | Способы лечения лимфом с использованием сочетания химиотерапевтического средства и il-2, и, не обязательно, антител анти-cd20 | |
| JP2021522246A5 (cg-RX-API-DMAC7.html) | ||
| KR20180017145A (ko) | 소양증의 치료 | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| DE112008000888T5 (de) | Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen | |
| JP2018529747A5 (cg-RX-API-DMAC7.html) | ||
| JP2024535880A5 (cg-RX-API-DMAC7.html) |